UNITED
STATES SECURITIES AND
EXCHANGE
COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): February 15, 2006
GAMMACAN
INTERNATIONAL, INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or
other jurisdiction of incorporation)
0-32835
(Commission
File Number)
33-0956433
(IRS
Employer Identification No.)
11
Ben Gurion St., 54100 Givat Shmuel, Israel
(Address
of principal executive offices and Zip Code)
Registrant's
telephone number, including area code: 972
3 5774475
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
8.01 Other Events.
On
February 15, 2006, Gammacan International, Inc. filed two provisional
applications for patents with the United States Patent and Trademark Office.
One
application entitled “Immunoglobulins from Vitiligo Patients for Treatment of
Melanoma” is for a patent for the use of immunoglobulins and their functional
fragments isolated from vitiligo or melanoma patients in the treatment of
melanoma. The other application is entitled “Plasma from Vitiligo Patients for
Treatment of Melanoma and is for a patent for the use of plasma containing
antibodies directed against melanoma in the treatment of melanoma.
Item
9.01 Financial Statements and Exhibits.
(c)
|
Exhibits.
|
|
|
|
|
|
99.1
|
Press
Release, dated February 28, 2006, issued by GammaCan International,
Inc.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
GAMMACAN
INTERNATIONAL, INC. |
|
|
|
|
By: |
/s/ VERED
CAPLAN |
|
Vered
Caplan,
Chief
Executive Officer
|
|
|
|
Date:
February 28, 2006
|